Featured Research

from universities, journals, and other organizations

Safe, Well-tolerated, And Effective Treatment For Metastatic Esophageal Cancer

Date:
March 5, 2009
Source:
World Journal of Gastroenterology
Summary:
Patients with metastatic esophageal squamous cell cancer face a dismal prognosis, as no effective standard chemotherapy exists. A research group in China investigated the efficacy, toxic reaction and survival period of Oxaliplatin combined with capecitabine in treatment of patients with in patients with metastatic esophageal squamous cell cancer, and assessed the efficacy, toxicity and survival of the combination therapy.

Metastatic esophageal squamous cell cancer has very poor prognosis. Conventional surgery is considered the most effective treatment, but many cases are inoperable at the time of diagnosis.

Related Articles


More recently, chemotherapy has shown activity in metastatic ESCC. However, no generally accepted standard chemotherapy for advanced. In addition, more and more people pay close attention to the research of optimizing chemotherapy regimen.

Oxaliplatin is one kind of chemotherapeutic drug belonged to the third generation of platinum, which has played an important role in the treatment of colon and rectum cancer and other solid tumors. It has the synergistic effect with 5-FU with the slighter digestive tract reaction and hematotoxicity. Capecitabine which has the slighter side effect is the prosoma of 5-FU and can be taken orally and rapidly absorbed as an intact molecule in the gastrointestinal tract.

A research article to be published on February 21, 2009 in the World Journal of Gastroenterology addresses this question. The research team led by Dr. Qin, Professor Gu and Professor Zhao from Department of Medical Oncology, First Affiliated Hospital of Medical School of Xi'an Jiaotong University, evaluated the efficacy toxic reaction and survival period of Oxaliplatin combined with capecitabine in treatment of patients with in patients with metastatic esophageal squamous cell cancer.

In their study, patients with metastatic metastatic ESCC were treated with oxaliplatin 120 mg/m2 intravenously on day 1 and capecitabine 1000 mg/m2 orally twice daily on days 1 to 14 in a 21-day treatment cycle as palliative chemotherapy. Each patient received at least two cycles. The efficacy, side effects and survival were evaluated then. Treatment was continued until unacceptable toxicity or disease progression.

Out of the 64 patients whose response could be evaluated, the partial response was 43.8%, Stable disease (SD) rate was 47.9% (26/ 64), and disease progression (PD) rate was 15.6% (10/ 64). The clinical benefit rate (PR + SD) was 84.4%. The median overall survival was 10.0 months (95% CI 8.3-11.7 months,respectively. It showed an improvement for quality of life after the chemotherapy

"Capecitabine was given orally twice daily on days 1 to 14 in a 21-day treatment cycle" Said Dr. Zhao. "It showed that this treatment can be given on outpatient basis, therefore the economic burden of the patients can be reduced."

The investigators believed that the oxaliplatin combined with capecitabine treatment provides a safe, well-tolerated, and effective treatment for patients with metastatic ESCC.


Story Source:

The above story is based on materials provided by World Journal of Gastroenterology. Note: Materials may be edited for content and length.


Journal Reference:

  1. Qin et al. Combined treatment of oxaliplatin and capecitabine in patients with metastatic esophageal squamous cell cancer. World Journal of Gastroenterology, 2009; 15 (7): 871 DOI: 10.3748/wjg.15.871

Cite This Page:

World Journal of Gastroenterology. "Safe, Well-tolerated, And Effective Treatment For Metastatic Esophageal Cancer." ScienceDaily. ScienceDaily, 5 March 2009. <www.sciencedaily.com/releases/2009/02/090223091759.htm>.
World Journal of Gastroenterology. (2009, March 5). Safe, Well-tolerated, And Effective Treatment For Metastatic Esophageal Cancer. ScienceDaily. Retrieved October 25, 2014 from www.sciencedaily.com/releases/2009/02/090223091759.htm
World Journal of Gastroenterology. "Safe, Well-tolerated, And Effective Treatment For Metastatic Esophageal Cancer." ScienceDaily. www.sciencedaily.com/releases/2009/02/090223091759.htm (accessed October 25, 2014).

Share This



More Health & Medicine News

Saturday, October 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

IKEA Desk Converts From Standing to Sitting With One Button

IKEA Desk Converts From Standing to Sitting With One Button

Buzz60 (Oct. 24, 2014) IKEA is out with a new convertible desk that can convert from a sitting desk to a standing one with just the push of a button. Jen Markham explains. Video provided by Buzz60
Powered by NewsLook.com
Ebola Protective Suits Being Made in China

Ebola Protective Suits Being Made in China

AFP (Oct. 24, 2014) A factory in China is busy making Ebola protective suits for healthcare workers and others fighting the spread of the virus. Duration: 00:38 Video provided by AFP
Powered by NewsLook.com
WHO: Millions of Ebola Vaccine Doses by 2015

WHO: Millions of Ebola Vaccine Doses by 2015

AP (Oct. 24, 2014) The World Health Organization said on Friday that millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines would start being tested in March. (Oct. 24) Video provided by AP
Powered by NewsLook.com
Doctor in NYC Quarantined With Ebola

Doctor in NYC Quarantined With Ebola

AP (Oct. 24, 2014) An emergency room doctor who recently returned to the city after treating Ebola patients in West Africa has tested positive for the virus. He's quarantined in a hospital. (Oct. 24) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins